Promotion of Dr Howie McKibbon to Chief Operating Officer

/in , , , /by

Botanix has announced the promotion of Dr Howie McKibbon to the role of Chief Operating Officer, from his current position as Chief Commercial Officer.

Howie has more than 20 years of leadership experience in the pharmaceutical industry. He has launched 15 products including 11 in dermatology, and managed over 30 dermatology products. Importantly too, he played a significant role in two of the world’s largest dermatology acquisitions with combined valuations of $7.8 billion. 

Howie’s role will be expanded to include responsibility for all commercial, manufacturing, medical affairs and regulatory activities. We believe the breadth and depth of his experience will be invaluable as the Company prepares for FDA mid-cycle review of our lead asset, Sofpironium Bromide in late Q1 2023.  

Click here to read today’s ASX release.

Research Report by Euroz Hartleys – 14 October 2022

/in , , /by

Botanix is pleased to share a recent analyst report published by Euroz Hartleys following last week’s announcement of positive results from our BTX 1702 Phase 1b/2 clinical trial for rosacea. 

Analyst Seth Lizee noted:

“We believe the rosacea treatment universe is prime for disruption, with a gap in the market for drugs that can deliver similar efficacy without the side effects and limitations. 

“Overall, these results strengthen BOTs already valuable pipeline of products, led by its lead asset Sofpironium Bromide, which the company recently submitted a New Drug Application (NDA) for to the FDA (12 month review process).”

Read the full report.

Research Report by Euroz Hartleys – 17 August 2022

/in , , /by

Botanix (ASX:BOT) is pleased to advise that leading adviser Euroz Hartleys has released an analysis outlining the strong market opportunities for our most recent asset acquisition, Sofpironium Bromide.

Within the report, analyst Seth Lizee commented:

“Sofpironium Bromide’s target patient population is estimated to be ~3.7 million people in the United States, equal to the estimated number of patients with severe axillary hyperhidrosis seeking treatment…Even modest market penetration can translate into significant revenues.”

Read the full report.

Euroz Hartleys Report | 7 July 22

/in , , /by

Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company announcement that the FDA filing timeline for Sofpironium Bromide had been accelerated.

Click here to view the report.

Euroz Hartleys Report | 22 June 2022

/in , , /by

Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the acquisition of our dermatology asset Sofpironium Bromide.

Click here to view the report.

Herald Sun + Daily Telegraph | Sofpironium Bromide Story

/in , /by

🗞 MAKING HEADLINES

Herald Sun Reporter, Owen Leonard, met with Botanix executives while they were in Australia this week and has published a story about the Company’s recent acquisition of Sofpironium Bromide.

This novel potential treatment for primary axillary hyperhidrosis, a medical condition that results in excessive underarm sweat, is bringing new hope for sufferers.

Botanix Executive Director, Matthew Callahan, explained why it could fill a market gap:

“At the moment, to treat it, you’ve got a couple of options. You’ve got antiperspirants – covers up the smell but does nothing to actually have an effect on the excessive sweating – and at the other extreme, you’ve got surgery, where they’ll actually go in and cut the nerve to stop the signals getting to the sweat gland to stop you sweating excessively.

“In between, there’s been a lot of drugs that have been around for decades that don’t work very well and have all sorts of nasty side effects.”

Click here to read the story.

Euroz Hartleys Report | ‘Transformational Acquisition’

/in , /by

Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the Company’s recent acquisition of Sofpironium Bromide.

The deal has been called a “transformational acquisition”.

Click here to view the report.

Euroz Hartleys Report | 4 May

/in , , /by

Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the acquisition of our dermatology asset Sofpironium Bromide.

Click here to view the report.

Euros Hartley Report | 29 April 2022

/in , , /by

Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s March quarterly report.

Click here to view the report.

Eurox Hartleys Report | 28 April 2022

/in , , /by

Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the Company’s announcement that the US FDA has granted BOT Qualified Infectious Disease Product (QIPD) designation for BTX1801.

Click here to view the report.